Compared to PD-1/PD-L1 inhibitors, CTLA-4 inhibitors were weak in treating small cell lung cancer with high side effects, which may be the reason why there were fewer RCTs of CTLA inhibitors for small cell lung cancer. This evidence concerns the gene CTLA4 and small cell lung carcinoma.